Newsletter | February 18, 2026

02.18.26 -- Building Safer CRISPR Medicines For CVD With Benjamin Oakes

SPONSOR

Join Cell & Gene Live Chief Editor Erin Harris on February 19, at 11am Eastern for Building Smarter Cell Therapies with AI and Synthetic Biology. In this live event, experts will explore how AI and synthetic biology are being applied to engineer more precise, controllable, and scalable cell therapies. Register for free thanks to support from our sponsor BD Biosciences.

FOCUS ON TRANSLATIONAL RESEARCH

Building Safer CRISPR Medicines For CVD With Benjamin Oakes

In episode 121 of Cell & Gene: The Podcast, Host Erin Harris talks to Scribe Therapeutics' CEO and Co-Founder Benjamin Oakes about building next‑generation CRISPR and epigenetic editing tools to expand beyond rare disease into common cardiometabolic indications.

Accelerate Discovery With AI And Multi-Omics In Translational Research

Modernize your translational pipeline by integrating multi-omic data with AI. Learn how these computational tools identify novel targets and streamline the path from lab to clinical strategy.

Bridging Discovery And CMC With Rapid Pools

Learn how early stable CHO expression data reveals manufacturability issues in complex antibodies that transient screening misses, with case studies showing how this changes lead selection.

Harnessing The Power Of Cell And Gene Therapy In Oncology

Advances in oncology, specifically in CAR T-cell therapies and TILs, are leading the way in cell and gene therapy. However, costs and complex regulations present challenges.

Technical Guidance For Consistent Fluorescent Western Blot Results

Review this step-by-step guidance for fluorescent western blot detection, including membrane prep and antibody handling, to improve signal clarity and consistency across imaging platforms.

APOEε4: Why Alzheimer's "Prophet" Struggles To Become A Therapeutic "Savior"

Explore the technical hurdles of APOE-targeted development and the precision tools, including target proteins and pre-formed fibrils, required to bridge the gap from risk detection to commercial success.

Modeling The Human Liver Sinusoid With Organ-On-A-Chip Technology

Eliminate drug absorption bias with an organ-on-a-chip model that replicates human liver architecture. Review the technical specs of a platform engineered for more accurate toxicological screening.

TRANSLATIONAL RESEARCH SOLUTIONS

Compact And Tunable Absorbance Microplate Readers - Danaher Life Sciences

Fast And Reliable Real-Time Imaging - BD Biosciences

Connect With Cell & Gene: